Your donations to The BRAIN Foundation are tax-deductible.
EID: 83-4072118
Understanding ASD through animal models, tissue cultures and organoids
Treatments in the FDA pipeline undergoing clinical trials
Biotech startups and pharmaceutical companies: Novel ASD therapeutics
100+ Researcher Participants
10 BRAIN Foundation Principal Investigators Funded
$1 Million+ in Research Grants Facilitated
150+ Physicians
Presentations by selected researchers on new cutting-edge topics in basic science and translational research. Proposals for future studies, or results from ongoing studies may be presented. Awards for Most Innovative and Most Impactful research will be presented.
Researchers funded by the BRAIN Foundation will present their proposals and research updates.
Physician education track will include talks to disseminate valuable clinical information, treatment studies, and translational research.
Industry Presentations including novel therapeutics and scientific data from industry leaders on track for FDA approval.
The roundtable will discuss the case of relapsing-remitting neuropsychiatric and other symptoms in adolescents/adults with ASD diagnosis. Case studies will be presented, and the working group’s roadmap to develop a case for diagnosis and treatment (with existing medications) in this subgroup will be discussed.
Participants: Stanford, UC Davis, Wake Forest, and a number of physicians and parents
Chair: Gabriel Belfort, MD, PhD
Participants: Vice President, Clinical Development Sciences, Axial Therapeutics Inc.
A discussion to further the discovery of biomarkers for core symptoms and comorbidities affecting those with ASD diagnosis. Biomarker discovery has largely focussed on diagnosis; we will further the conversation on possible biomarkers to measure treatment response, which will accelerate the discovery of novel and effective therapeutics.
Chair: John Slattery, CEO, BioRosa Technologies.
Participants: UC Davis, Stanford, Wake Forest, BioROSA, and other industry participants.
This roundtable will discuss seizures in ASD with an emphasis on adolescents and adults. The discussion will include preventive diagnostics, treatments and evidence, and case studies.
Chair: Dr. Richard Frye, MD, PhD, Director of Research at Rossignol Medical Center
Included in this conference is an outdoor networking and socializing opportunity for speakers to stimulate new connections and ideas in a picturesque setting in Livermore Wine Country, East Bay, California.
The venue, people and events were top-notch. If they do it again, I would highly encourage those interested in learning first-hand about emerging autism research and clinical trials to attend this valuable event.
Synchrony 2019 facilitated collaboration between researchers, clinicians and parent advocates on complex autism related issues that can only be fully answered through multidisciplinary collaboration.
